Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b.
Giovannoni
Gavin
G
D000906:Antibodies / Q000276:immunology*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000627:therapeutic use*; D008137:Longitudinal Studies; D020528:Multiple Sclerosis, Chronic Progressive / Q000276:immunology* / Q000628:therapy*; D011237:Predictive Value of Tests; D012107:Research Design; D018401:Sample Size; D012680:Sensitivity and Specificity
D000906:Antibodies; D000068576:Interferon beta-1b; D016899:Interferon-beta